Company Hoth Therapeutics, Inc.

HOTH

US44148G2049

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Delayed Nasdaq Other stock markets 10:49:52 2024-05-13 EDT			5-day change	1st Jan Change
1.2 ^USD	+2.55%		+2.56%	-16.67%

03-28	Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-19	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimerâs or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Number of employees: 3

Managers	Title	Age	Since
Robbie Knie CEO	Chief Executive Officer	55	17-05-15
David Briones DFI	Director of Finance/CFO	48	19-03-04
Hayley Springer COO	Chief Operating Officer	-	17-11-30

Members of the board	Title	Age	Since
Robbie Knie CEO	Chief Executive Officer	55	17-05-15
David Sarnoff BRD	Director/Board Member	56	18-07-31
Wayne Linsley BRD	Director/Board Member	67	20-04-14
Graig Springer BRD	Director/Board Member	44	20-01-31
Jeff Pavell BRD	Director/Board Member	57	22-12-06

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,888,804	4,817,410 ( 98.54 %)	0	98.54 %

Name	Equities	%	Valuation
Armistice Capital LLC 4.669 %	228,278	4.669 %	267 085 $
Vanguard Group, Inc. (Subfiler) 0.7937 %	38,804	0.7937 %	45 401 $
Jeff Pavell 0.7340 %	35,882	0.7340 %	41 982 $
Robbie Knie 0.6777 %	33,131	0.6777 %	38 763 $
Geode Capital Management LLC 0.4807 %	23,501	0.4807 %	27 496 $
UBS Securities LLC 0.1288 %	6,297	0.1288 %	7 367 $
UBS Financial Services, Inc. 0.0440 %	2,150	0.0440 %	2 516 $
Tower Research Capital LLC 0.0319 %	1,558	0.0319 %	1 823 $
David Sarnoff 0.0205 %	1,000	0.0205 %	1 170 $
Brewin Dolphin Wealth Management Ltd. 0.004909 %	240	0.004909 %	281 $

Hoth Therapeutics, Inc.

590 Madison Avenue 21st floor

10020, New York

http://www.hoththerapeutics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.17 USD

Average target price

5.5 USD

Spread / Average Target

+370.01%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
HOTH THERAPEUTICS, INC.	-16.67%	5.72M
ELI LILLY AND COMPANY	+29.07%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.82%	361B
MERCK & CO., INC.	+17.75%	329B
ABBVIE INC.	+4.54%	284B
ASTRAZENECA PLC	+16.06%	240B
NOVARTIS AG	+9.32%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.85%	166B

Other Pharmaceuticals